Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:9042559rdf:typepubmed:Citationlld:pubmed
pubmed-article:9042559lifeskim:mentionsumls-concept:C1555794lld:lifeskim
pubmed-article:9042559lifeskim:mentionsumls-concept:C0019139lld:lifeskim
pubmed-article:9042559lifeskim:mentionsumls-concept:C0220812lld:lifeskim
pubmed-article:9042559lifeskim:mentionsumls-concept:C0205164lld:lifeskim
pubmed-article:9042559lifeskim:mentionsumls-concept:C1704419lld:lifeskim
pubmed-article:9042559pubmed:dateCreated1997-4-30lld:pubmed
pubmed-article:9042559pubmed:abstractTextThe objective of this analysis was to evaluate the socioeconomic consequences of routine administration of low molecular weight heparin (LMWH) as thromboprophylaxis in patients undergoing total hip arthroplasty, on the basis of data from a number of clinical studies. Despite the higher direct costs associated with LMWH, this regimen was more cost effective per thromboembolic complication prevented than no prophylaxis, dextran 70, or low dose unfractionated heparin. A sensitivity analysis was performed to address the outcome when the main factors in the economic analysis were changed; this had no significant effect on the conclusions of the study.lld:pubmed
pubmed-article:9042559pubmed:languageenglld:pubmed
pubmed-article:9042559pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9042559pubmed:citationSubsetIMlld:pubmed
pubmed-article:9042559pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9042559pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9042559pubmed:statusMEDLINElld:pubmed
pubmed-article:9042559pubmed:issn0012-6667lld:pubmed
pubmed-article:9042559pubmed:authorpubmed-author:LassenM RMRlld:pubmed
pubmed-article:9042559pubmed:authorpubmed-author:BorrisL CLClld:pubmed
pubmed-article:9042559pubmed:issnTypePrintlld:pubmed
pubmed-article:9042559pubmed:volume52 Suppl 7lld:pubmed
pubmed-article:9042559pubmed:ownerNLMlld:pubmed
pubmed-article:9042559pubmed:authorsCompleteYlld:pubmed
pubmed-article:9042559pubmed:pagination42-6lld:pubmed
pubmed-article:9042559pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:9042559pubmed:meshHeadingpubmed-meshheading:9042559-...lld:pubmed
pubmed-article:9042559pubmed:meshHeadingpubmed-meshheading:9042559-...lld:pubmed
pubmed-article:9042559pubmed:meshHeadingpubmed-meshheading:9042559-...lld:pubmed
pubmed-article:9042559pubmed:meshHeadingpubmed-meshheading:9042559-...lld:pubmed
pubmed-article:9042559pubmed:meshHeadingpubmed-meshheading:9042559-...lld:pubmed
pubmed-article:9042559pubmed:meshHeadingpubmed-meshheading:9042559-...lld:pubmed
pubmed-article:9042559pubmed:meshHeadingpubmed-meshheading:9042559-...lld:pubmed
pubmed-article:9042559pubmed:meshHeadingpubmed-meshheading:9042559-...lld:pubmed
pubmed-article:9042559pubmed:year1996lld:pubmed
pubmed-article:9042559pubmed:articleTitleThromboprophylaxis with low molecular weight heparin after major orthopaedic surgery is cost effective.lld:pubmed
pubmed-article:9042559pubmed:affiliationVenous Thrombosis Group, Aalborg Hospital, Denmark.lld:pubmed
pubmed-article:9042559pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:9042559pubmed:publicationTypeComparative Studylld:pubmed